glycooptimized trastuzumab-GEX

{
  "id": "MLC-T-ONC-013984",
  "term": "glycooptimized trastuzumab-GEX",
  "field": "Oncology and biomedicine",
  "definition": "A glycoengineered form of a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. Glycooptimized trastuzumab-GEX specifically binds to the extracellular domain of HER2, thereby inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. This eventually results in apoptosis and growth inhibition of tumor cells. HER2, a member of the receptor tyrosine kinase EGFR superfamily, is overexpressed on the cell surfaces of various solid tumors. This agent has a specific glycosylation profile that may enhance its ADCC response against HER2-expressing tumor cells.",
  "synonyms": [
    "GT-Mab 7.3-GEX",
    "anti-HER2 monoclonal antibody GT-Mab 7.3-GEX"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/glycooptimized-trastuzumab-gex/"
}